Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints BioSpaceOver the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) BioSpace Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize. Neuroscience Read full story Post navigation Previous: Norgine gets first EU approval for WHIM syndrome therapyNext: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026